Podiatrists in Opelousas, LA Accepting Medicare

5 Podiatrists found. Showing 1 - 5

George R Smith, DPM Podiatrist - Foot & Ankle Surgery Medicare: Medicare Enrolled Practice Location: 2848 S Union St, Opelousas, LA 70570 Phone: 337-942-7567    Fax: 337-948-4993

Dr. Vinoth Muthalagappan, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2848 S Union St, Opelousas, LA 70570 Phone: 337-942-7567    Fax: 379-484-9933

Lon M. Baronne, DPM Podiatrist - Foot & Ankle Surgery Medicare: Accepting Medicare Assignments Practice Location: 2848 S Union St, Opelousas, LA 70570 Phone: 337-942-7567    Fax: 337-948-4993

Dr. David V. Maraist Jr., DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2848 South Union, Opelousas, LA 70570 Phone: 337-942-7567    Fax: 337-948-4993

Baronne Foot Center Podiatrist - Foot & Ankle Surgery Medicare: Medicare Enrolled Practice Location: 2848 S Union St, Opelousas, LA 70570 Phone: 337-948-7567    Fax: 337-948-4993

News Archive

FDA grants accelerated approval to ARIAD's Iclusig for treatment of CML, Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

TRION Pharma GmbH has announced that the results from two different studies demonstrate catumaxomab's capacity to activate the immune system in a way that can otherwise only be achieved through vaccination. The data were obtained by two independent research teams using catumaxomab in malignant ascites and gastric cancer, respectively. The results were recently presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

New data demonstrates improved outcomes in psoriasis patients treated with Daivobet gel

Interim results from one of the largest and longest clinical trials ever conducted for a topical treatment in psoriasis showed that after eight weeks of treatment with calcipotriol/betamethasone dipropionate (Daivobet gel), the treatment was highly efficacious, preferred by patients and improved patients' and the physicians' assessments of disease severity.

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC).

Read more Medical News

› Verified 1 days ago